# Apoteket AB account plan

> Apoteket is Sweden's state-owned pharmacy chain: SEK 27,062 million 2025 net sales, 398 pharmacies, e-commerce and dose services, 4,440 employees.

## At a glance

Apoteket AB (publ) is a pharmacy company wholly owned by the Swedish state and run on market terms, headquartered in Solna. It sells prescription and over-the-counter medicines and other pharmacy products through about 395 outpatient pharmacies, 526 pharmacy agents, apoteket.se and an app, and supplies medicines, dose packaging and pharmacy services to regions, municipalities and care providers. FY2025 net sales were SEK 27,062 million (+6.6%), operating profit SEK 564 million (margin 2.1%) and net profit SEK 665 million; it had 4,440 employees at 31 December 2025. Rasmus Nerman has been CEO since 2022 and Ingrid Bonde chairs the board.

## Business units

- **Konsumentmarknaden (consumer market)** (78% of 2025 sales (SEK 21,151 million)): Outpatient pharmacies (398 at 30 September 2026), pharmacy agents and e-commerce via apoteket.se and the app, shipped from an automated e-pharmacy in Eskilstuna. Growth in January-September 2026 (+6.5% to SEK 16,718 million) came mainly from prescribed medicines in stores, with continued high demand for obesity drugs, and from self-care in stores and online. Business area Butik is led by Nina Eriksson and E-handel by Mikael Meijer.
- **Dos- och vårdmarknaden (dose and care market)** (22% of 2025 sales (SEK 5,911 million)): Drug supply and compounding for regions, hospital pharmacy operations, dose-packaged medicines (Apodos, Dospac, 72,000 dose customers), specialty drugs and pharmacy consultants, plus preparedness work with the Swedish Armed Forces. Sales rose 38.9% to SEK 5,592 million in January-September 2026, mainly from the Region Skåne contract started in September 2025. Led by Andreas Skillstedt.

## Strategic priorities

- **Reaching the 3% operating margin target**: The long-term operating margin target is 3.0%; the rolling 12-month margin to September 2026 was 2.3%, against 2.1% in 2025.
- **Omnichannel and e-commerce**: E-commerce reached 25.6% of Swedish pharmacy market sales in 2025; Apoteket integrates pharmacies, web, app and digital services while continuing to open and upgrade pharmacies, with several openings planned for autumn 2026 and 2027.
- **Growing dose and care contracts**: New contracts with Region Skåne (from September 2025), Region Halland and Kriminalvården (from November 2025), and an expanded role in the Armed Forces' emergency stockpiles.
- **A bigger clinical role for pharmacists**: The inhaler-guidance service has been rolled out in all outpatient pharmacies; Apoteket tested remote pharmacists via an iPad in December 2024.
- **Data and AI**: Apoteket launched a new analytics platform and decision support in 2025, has an internal AI council, and says AI is gradually becoming part of daily work.
- **Climate targets**: Cut emissions from goods transport, energy, company cars and refrigerants by 70% by 2030 versus 2020, and have 90% of suppliers by purchase cost on the Science Based Targets initiative (61% in 2025).

## Latest results

In Q3 2026 (July-September) net sales rose 9.5% to SEK 7,251 million and operating profit to SEK 235 million from SEK 158 million, a 3.2% margin (2.4%), helped by consumer sales, better pricing and improved profitability in dose and care. For January-September 2026 net sales were SEK 22,310 million (+13.1%), operating profit SEK 546 million (margin 2.4%) and net profit SEK 607 million. Costs rose mainly from tech investments and the start-up of the new care contract. The report gives no numeric guidance beyond the long-term targets.

## Investments and deals

- **Store, contract and IT investment**: Investments were SEK 183 million in 2025 (92 in 2024), mainly store fittings, adaptations for the Region Skåne contract and new IT solutions; SEK 106 million in January-September 2026.
- **Pharmacy network**: Six pharmacies were opened and three closed in 2025, with more openings planned for autumn 2026 and 2027.
- **Preparedness stocks**: Apoteket has raised stock levels on several medicines and taken expanded responsibility for parts of the Armed Forces' emergency stockpiles.

## Challenges and risks

- **Price pressure from online players**: Pure online competitors and the channel shift to e-commerce drive price pressure, while prescription reimbursement set by TLV is about break-even.
- **Pharmacist and IT skills shortage**: The pharmacist shortage forced Apoteket to adjust opening hours at about 150 pharmacies in summer 2025.
- **Security and cyber threats**: Apoteket had six robberies in 2025, four in vulnerable areas, requiring alarms, cameras and double staffing; cyber threats are becoming more sophisticated.
- **Dose and care profitability**: The annual report calls profitability in this market still challenging, as several supply contracts lost value while regions take work in-house.
- **Drug shortages and pension commitment**: Tariffs and disruptions sustain the risk of drug shortages, and the large pension commitment in Apotekets Pensionsstiftelse could require capital injections.

## What leadership says

> "Vi måste investera mer i säkerhet, bland annat i form av larm och kameror." — Rasmus Nerman, CEO, Tidningen Näringslivet interview, 11 August 2026, on pharmacy robberies (we must invest more in security, including alarms and cameras)

> "Apotekens tillgänglighet hotas av en växande brist på farmaceuter" — Rasmus Nerman, CEO, Svensk Farmaci feature on remote pharmacists, 28 October 2025 (pharmacy access is threatened by a growing pharmacist shortage)

> "Jag vill dock vara tydlig med att jag inte ser att farmaceuter på distans ska ersätta lokala farmaceuter utan komplettera vid behov." — Rasmus Nerman, CEO, Svensk Farmaci, 28 October 2025 (remote pharmacists should complement, not replace, local pharmacists)


## Where a supplier can help

- **Remote pharmacist platforms**: Tied to the pharmacist shortage and the clinical-role priority: a digital platform for remote consultations is what the CEO expects to be part of the solution.
- **Store security**: Tied to the security challenge: alarms, cameras, guarding and cash handling services address the stated costs in vulnerable areas.
- **Data, AI and analytics**: Tied to the data and AI priority and rising tech investment: analytics, decision support and AI tools for pharmacy and logistics workflows.
- **Logistics and compounding capacity**: Tied to the growing dose and care contracts: hospital supply, dose packaging, cold chain and preparedness stock solutions support contracts such as Region Skåne.
- **Low-emission transport**: Tied to the 70% emissions-cut target: fossil-free delivery and energy-efficiency suppliers fit a target missed so far (4.1 thousand tonnes CO2e in 2025 vs 3.4).

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Apotekets års- och hållbarhetsredovisning 2025 (Annual and Sustainability Report 2025)](https://www.apoteket.se/imagevault/publishedmedia/9qmyf4w3lam5ljzczugl/apoteket-arsredovisning-2025.pdf)

Annual report · 2026-03-06

- Apoteket AB is Sweden's state-owned pharmacy chain (wholly owned by the Swedish state, HQ Solna), with 395 outpatient pharmacies, 526 pharmacy agents (apoteksombud), e-commerce via apoteket.se and app, and services to healthcare providers; 4,440 employees at 31 December 2025.
- FY2025 net sales SEK 27,062 million (2024: 25,380), up 6.6%; operating profit SEK 564 million (670); operating margin 2.1% (2.6%), below the 3% long-term target; net profit SEK 665 million (722).
- Two markets: Konsumentmarknaden (consumer market: pharmacies + e-commerce) 78% of sales, SEK 21,151 million (+7.0%); Dos- och vårdmarknaden (dose and care market) 22%, SEK 5,911 million (+5.3%).
- Growth came from consumer sales and new care contracts: Region Skåne drug supply, inpatient dose and compounding (from September 2025), Kriminalvården (prison service) dose-dispensed drugs (from November 2025), and an expanded role in the Swedish Armed Forces' emergency stockpiles; the Region Västra Götaland dose contract ended in February 2025.
- Profit hit by a weak spring season in self-care, the lost dose contract, one-off development costs and start-up costs of the new care contract; investments rose to SEK 183 million (92).
- Swedish consumer pharmacy market grew 7.3% to SEK 68,041 million; e-commerce reached 25.6% (21.9%) of total pharmacy market sales; pure-play online competitors drive price pressure.
- Dividend: SEK 1,335 million paid in 2025 (ordinary 335 + extra 1,000 to align with the equity-ratio target); SEK 271 million proposed for 2025 (60% of pension-adjusted net profit).
- Priorities stated by CEO Rasmus Nerman: preparedness and stable supply, omnichannel e-commerce, continued investment in the physical network (six new pharmacies in 2025), and a bigger clinical role for pharmacists (e.g. inhaler guidance); risks include pharmacist and IT skills shortages, cyber threats, drug shortages, the pension commitment and a Swedish Competition Authority supervisory case.
- Climate target: cut emissions from goods transport, energy, company cars and refrigerants by at least 70% by 2030 versus 2020; 2025 outcome 4.1 thousand tonnes CO2e (3.4 in 2024); 61% of suppliers by purchase cost on SBTi (target 90%).

### [Delårsrapport januari - september 2026 (Interim report Q3 2026)](https://apoteket.imagevault.app/publishedmedia/2pln2fuxjnz7kxnhb6cp/Q3_2026_del-rsrapport_Apoteket_jan-sep.pdf)

Interim report · 2026-10-23

- Q3 2026 (July-September): net sales SEK 7,251 million (6,619), +9.5%; operating profit SEK 235 million (158); operating margin 3.2% (2.4%); net profit SEK 246 million (179). Report headline: "Starkt kvartal med ökad omsättning och förbättrat resultat".
- January-September 2026: net sales SEK 22,310 million (19,726), +13.1%; operating profit SEK 546 million (440); margin 2.4% (2.2%); net profit SEK 607 million (513).
- Konsumentmarknaden 9M: SEK 16,718 million (15,700), +6.5%, driven by prescribed medicines in stores (volume and higher average prices, with continued high demand for obesity drugs) and self-care growth in stores and online; 398 pharmacies.
- Dos- och vårdmarknaden 9M: SEK 5,592 million (4,026), +38.9%, mainly from the Region Skåne contract (from September 2025) and growth in existing supply contracts, partly offset by ended regional contracts; better operations in the new contracts improved results.
- Costs rose mainly from tech investments; AI is being built into daily ways of working. The inhaler-guidance pharmacy service is now in all outpatient pharmacies.
- Rolling 12-month margin 2.3% versus the 3.0% target; equity ratio 46.2% (target 35-45%); ROE 15.6%, ROCE 20.0%; 9M operating cash flow SEK 923 million (861); equity SEK 10,635 million.
- Policy: Apoteket is lobbying for sustainable pharmacy reimbursement, incl. in socio-economically vulnerable areas, and welcomes the government asking the Dental and Pharmaceutical Benefits Agency (TLV) to review pharmacies' finances.
- Average employees 3,388 in Q3 (3,179); no significant events during or after the period.

### [Delårsrapport januari - juni 2026 (Interim report Q2 2026)](https://www.apoteket.se/imagevault/publishedmedia/3zxa3uctz93ezwof7kyk/q2-2026-delarsrapport-apoteket-april-juni.pdf)

Interim report · 2026-07-16

- Q2 2026 (April-June): net sales SEK 7,545 million (6,683), +12.9%; operating profit SEK 183 million (163); operating margin stable at 2.4% (2.4%); net profit SEK 202 million (183).
- H1 2026: net sales SEK 15,059 million (13,107), +14.9%; operating profit SEK 311 million (282); margin 2.1% (2.2%); net profit SEK 361 million (334).
- Konsumentmarknaden H1: SEK 11,172 million (10,504), +6.4%, led by prescribed medicines in stores (higher average prices, mainly obesity drugs); self-care strengthened in Q2; 397 pharmacies.
- Dos- och vårdmarknaden H1: SEK 3,887 million (2,604), +49.3%, mostly from the Region Skåne contract (from September 2025) and growth in existing supply contracts.
- Costs up from the new care contract, targeted marketing campaigns and tech investments; several new pharmacy openings planned for autumn 2026 and 2027.
- CEO Rasmus Nerman welcomes government proposals on pharmaceutical services and a bigger role for pharmacists, and the government's mandate to TLV to review pharmacy reimbursement.
- AGM: SEK 271 million dividend for 2025; Ingrid Bonde re-elected chair; Johan Färnstrand joined the board, Barbro Fridén left.

### [Apotekets vd efter grova rånen: ”En rejäl klump i magen” (Tidningen Näringslivet)](https://www.tn.se/naringsliv/48752/apotekets-vd-efter-grova-ranen-en-rejal-klump-i-magen/)

Executive talk · Rasmus Nerman, CEO · 2026-08-11

- Interview with CEO Rasmus Nerman in Tidningen Näringslivet (11 August 2026) on robberies and the economics of pharmacies in vulnerable areas (utanförskapsområden).
- Apoteket Ekorren in Kortedala, Gothenburg, was robbed three times in six months in 2024, with hand grenades and a pistol; Apoteket stopped handling cash and narcotic-classified drugs there.
- Six robberies last year, four of them in vulnerable areas; none in Apoteket's stores so far this year.
- Costs are higher there: alarms, cameras, double staffing and at times guards escorting staff to and from work, while lower purchasing power cuts self-care sales.
- Prescription sales are close to break-even under TLV's reimbursement, so pharmacies rely on other products; he wants a support for pharmacies in vulnerable areas like the existing sparse-area grant (pharmacies more than 20 km from the nearest other pharmacy).
- Pharmacy numbers fell from 1,433 in 2020 to 1,397 at the turn of 2024/25 before ticking up to 1,400 in 2025; he sees a big risk that more will have to close.
- He calls Apoteket "lite av en institution" and a hub where anyone can get help without booking.

### [”Farmaceuter på distans kan vara lösningen” (Svensk Farmaci)](https://www.svenskfarmaci.se/2025/10/28/farmaceuter-pa-distans-kan-vara-losningen/)

Executive talk · Rasmus Nerman, CEO · 2025-10-28

- Svensk Farmaci feature (28 October 2025) on remote pharmacists (farmaceuter på distans), with Apoteket CEO Rasmus Nerman among four pharmacy-chain leaders interviewed.
- Pharmacist shortage forces closures or shorter hours: in summer 2025 Apoteket adjusted opening hours at about 150 pharmacies, fewer than in summer 2024.
- Nerman says remote pharmacists would make a noticeable positive difference for Apoteket, its staff and customers, and leave pharmacists more time for qualified medication advice.
- Apoteket tested it in December 2024: prescription customers in one pharmacy could meet a pharmacist digitally via an iPad.
- Benefits he cites: use pharmacists' skills nationwide, relieve individual pharmacies at volume peaks, better crisis preparedness, new career paths and flexibility.
- He stresses remote pharmacists should complement, not replace, local pharmacists; the set-up depends on what regulation allows, likely with a digital platform.

## Questions about Apoteket AB

### What does Apoteket do?

Apoteket runs pharmacies, pharmacy agents and e-commerce across Sweden, and supplies medicines, dose packaging and pharmacy services to regions, municipalities and care providers.

### What was Apoteket's revenue in 2025?

Net sales were SEK 27,062 million in 2025, up 6.6%, with operating profit of SEK 564 million.

### How many employees does Apoteket have?

Apoteket had 4,440 employees at 31 December 2025.

### Who owns and leads Apoteket?

Apoteket is wholly owned by the Swedish state. Rasmus Nerman is CEO and Ingrid Bonde chairs the board.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
